Goldman Sachs Group Inc Vincerx Pharma, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 631,397 shares of VINC stock, worth $517,745. This represents 0.0% of its overall portfolio holdings.
Number of Shares
631,397
Previous 631,424
0.0%
Holding current value
$517,745
Previous $454,000
62.56%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding VINC
# of Institutions
21Shares Held
4.8MCall Options Held
0Put Options Held
0-
Sage Rhino Capital LLC1.7MShares$1.4 Million0.1% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$731,2090.01% of portfolio
-
Armistice Capital, LLC New York, NY567KShares$464,9490.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA286KShares$234,8250.0% of portfolio
-
Geode Capital Management, LLC Boston, MA242KShares$198,0430.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $17.4M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...